GlobalData on MSN1d
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLC
The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Le Lézard1d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...
PharmiWeb1d
Boehringer’s zongertinib receives Priority Review…
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
CAPLYTA’S Strong Market Adoption Propels Its Rise As A Leading Antipsychotic Therapy | Delveinsight
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
Evolving Landscape Of Obesity: Key Market Insights Of Latest Published Different Types Of Obesity | Delveinsight
The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be fu ...
Contract Pharma2d
FDA Grants Priority Review to Boehringer Ingelheim’s NDA for Zongertinib
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...
HER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsight
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...
pharmaphorum2d
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
Targeted Oncology2d
FDA Grants Priority Review to Zongertinib in HER2-Mutant NSCLC
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...